¡®Much work remains to be done for new drug access in Korea'
By Eo, Yun-Ho | translator Kang, Shin-Kook
24.05.20 05:48:55
°¡³ª´Ù¶ó
0
Kyung-Eun Bae (Kay Bae ), Chair of the Korean Research-based Pharmaceutical Industry Association
"Government preferential measures are encouraging...should recognize the practical value of new drugs¡±
"Will continue discussions with the government to improve post-marketing management and expenditure structure.¡±
¡ãKyung-Eun Bae (Kay Bae ), Chair of the Korean Research-based Pharmaceutical Industry Association
Kyung-Eun Bae (Kay Bae, 53) has risen to become the 'center' of the pharmaceutical industry. After being appointed as the general manager to lead subsidiaries including Korea, New Zealand, and Australia of the Sanofi Group, Bae was also appointed Chair of the Korean Research-based Pharmaceutical Industry Association (KRPIA)Being appointed to head the association representing multinational pharmaceutical companies in Korea along with Sanofi Group¡¯s major Asia-Pacific countries, Bae has become a key figure in communicating with the industry and regulatory authorities, including Sanofi headquarters and the Korean government.
Bae¡¯s appointment came at the busiest time. Bae has receiv
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)